[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_98":99},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","tb0a180lly5j4blyg01nc7tpj","revision",2,"title","SSi Mantra 手术机器人系统提交 510(k) 申请回应","originalTitle","SS Innovations International, Inc. (0001676163) (Filer)","summary","SSi 提交 510(k) 申请回应 FDA 信息请求。SSi Mantra 手术机器人系统获 FDA 审核。该回应作为 8-K 文件附件披露。","reason","source",{"_11":88,"_89":90,"_91":92,"_93":57,"_94":95,"_96":97},"links",{"_85":86,"_63":87},"publishedAt","2026-10-13T13:26:00.000Z","discoveredAt","2026-10-13T13:42:00.246Z","timelineAt","category","tip","tags",[80,81,82,83,84],"stockSymbols",[79],"score",30,"selected",false,"channel","news","story",{"_72":73,"_15":16},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fRR6TNdd5Lps",{"_72":73,"_15":16},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","5ef3564f-9dfd-4ba0-9682-8b10daf6575e",{"_72":73,"_15":16},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

WASHINGTON,\nD.C. 20549

FORM\n8-K

Pursuant\nto Section 13 or 15(d) of The Securities Exchange Act of 1934

Date\nof report (Date of earliest event reported): October 13, 2026

SS\nINNOVATIONS INTERNATIONAL, INC.

(Exact\nname of registrant as specified in its charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n

Florida		001-42615		47-3478854
(State or Other Jurisdiction \n of Incorporation)		(Commission File Number)		(IRS Employer \n Identification No.)

\n \n \n \n \n \n \n \n \n

405,\n 3rd Floor, iLabs Info Technology Centre

Udyog\n Vihar, Phase III

Gurugram,\n Haryana India

122016

(Address of Principal Executive\n Offices)

(Zip Code)

Registrant’s\ntelephone number, including area code: +91 73375 53469

(Former\nname or former address, if changed since last report)

Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions (see General Instruction A.2. below):

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

☐	Written communications\n pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant\n to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications\n pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications\n pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities\nregistered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each Class		Trading\n Symbol		Name\n of each exchange on which registered
Common Stock		SSII		The Nasdaq Stock Market\n LLC

Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging\ngrowth company ☐

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As\nused in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the\nCompany,” “we,” “us” and “our” refer to SS Innovations International,\nInc. and its subsidiaries.

Item\n8.01 Other Events.

On\nOctober 13, 2026, SSi issued a press release announcing that, on October 5, 2026, the Company submitted its response to a request for\nadditional information letter received from the United States Food and Drug Administration with respect to its 510(k) application for\nSSi’s SSi Mantra surgical robotic system.

A\ncopy of the press release is included as Exhibit 99.1 to this Current Report.

Item\n9.01 Financial Statements and Exhibits.

(d)\nExhibits

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit No.		Description
99.1		Press Release, dated October 13, 2026
104		Cover Page Interactive\n Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Dated: October 13, 2026	SS INNOVATIONS INTERNATIONAL, INC.

	By:	/s/\n Sudhir Srivastava
		Sudhir Srivastava, M.D.
		Chairman and Chief Executive\n Officer

","zhKind","complete","SSII","政策与监管","财报","IPO","退市","停复牌","aihot","/items/tb0a180lly5j4blyg01nc7tpj","https://www.sec.gov/Archives/edgar/data/1676163/000121390026108792/0001213900-26-108792-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792108800&sig=e4adf00b596060d2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792108800&sig=208b33ec2756b0ea 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792108800&sig=786fcd6a5ff8379c 96w","changelogVersion","2026-10-01T08:00"]